ISSN 2152-2650 Volume 24 Supplement 1 September 2025 In This Supplement SOHO2024 Supplement CLML Cover_Clinical Lymphoma Myeloma & Leukemia Cover 209.5x276 7/3/2024 4:20 PM Page 1 ISSN 2152-2650 Volume 25, Supplement 1 September 2025
www.soho.click/2025 Society of Hematologic Oncology Thirteenth Annual Meeting September 3–6, 2025 Location: Houston, Texas, USA & Virtual Venue (Hybrid Event) Organizing Committees SOHO Board of Directors Phillip Scheinberg, MD, President & Chairperson of the Board John DiPersio, MD, President-Elect Guillermo Garcia-Manero, MD, Immediate Past President Hagop Kantarjian, MD, Secretary Anthony H. Goldstone, CBE, FRCP, Past President Dieter Hoelzer, MD, PhD, Past President Alan List, MD, Past President Sagar Lonial, MD, FACP, Past President SusanM. O’Brien,MD, Past President Ching-Hon Pui, MD, Past President Moshe Talpaz, MD, Past President Julie Vose, MD, Board Member Janet Cesak, MBA, BS, Executive Director (non-voting) SOHO Steering Committee Hagop Kantarjian, MD, Chair Elias Anaissie, MD Stephen M. Ansell, MD, PhD Renier Brentjens, MD, PhD Sabina Chiaretti, MD, PhD Charles Craddock, CBE, FRCP, FRCPath, DPhil, FMedSci Claire Dearden, BSc, MBBS, MD, FRCP, FRCPath John DiPersio, MD, PhD Guillermo Garcia-Manero, MD Sergio Giralt, MD Anthony Goldstone, CBE, FRCP, FRCPath Claire Harrison, MD, DM, FRCP, FRCPath Dieter Hoelzer, MD, PhD Sundar Jagannath, MD Rami S. Komrokji, MD Jeffrey Lancet, MD Suzanne Lentzsch, MD, PhD Alan List, MD Sagar Lonial, MD, FACP Bob Löwenberg, MD, PhD Selina Luger, MD Thomas G. Martin, MD María-Victoria Mateos, MD, PhD Alison Moskowitz, MD Charles G. Mullighan, MBBS (Hons), MSc, MD SusanO’Brien,MD Barbara Pro, MD Ching-Hon Pui, MD Paul Richardson, MD Valeria Santini, MD Phillip Scheinberg, MD, PhD David Scheinberg, MD, PhD Charles A Schiffer, MD Laurie H. Sehn, MD, MPH John Seymour, MBBS, FRACP, PhD Elizabeth Shpall, MD Wendy Stock, MD Richard Stone, MD Moshe Talpaz, MD Julie Vose, MD, MBA
SOHO Education Committee Sagar Lonial, MD, FACP, Chair Sairah Ahmed, MD Pamela Allen, MD, MSc Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD Michael Andreeff, MD, PhD Stephen M. Ansell, MD, PhD Martha Arellano, MD Catherine Bollard, MD, MBChB Prithviraj Bose, MD Massimo Breccia, MD Renier Brentjens, MD, PhD Jorge E. Cortés, MD Charles Craddock, CBE, FRCP, FRCPath, DPhil, FMedSci Nick Cross, MA, PhD, FRCPath Naval Daver, MD Daniel DeAngelo, MD, PhD Michael Deininger, MD, PhD Meletios A. Dimopoulos, MD Angela Dispenzieri, MD Barbara Eichhorst, MD Pierre Fenaux, MD, PhD Alessandra Ferrajoli, MD Adele K. Fielding, MD, PhD Guillermo Garcia-Manero, MD Paolo Ghia, MD, PhD Sergio Giralt, MD Lucy A. Godley, MD, PhD Alex Herrera, MD Dieter Hoelzer, MD, PhD Elias Jabbour, MD Joseph Jurcic, MD Brad S. Kahl, MD Partow Kebriaei, MD Thomas Kipps, MD, PhD Rami S. Komrokji, MD Amrita Y. Krishnan, MD, FACP Jeffrey Lancet, MD Mary Jo Lechowicz, MD Suzanne Lentzsch, MD, PhD Georg Lenz, MD Jeffrey H. Lipton, MD, PhD, FRCPC Alan List, MD Bob Löwenberg, MD, PhD Selina Luger, MD Matthew A. Lunning, DO, FACP Kami J. Maddocks, MD Thomas G. Martin, MD John O. Mascarenhas, MD Marcela V. Maus, MD, PhD Laura C. Michaelis, MD Mohamad Mohty, MD, PhD Franck Morschhauser, MD, PhD Alison Moskowitz, MD Loretta Nastoupil, MD SusanO’Brien,MD KristenO’Dwyer, MD, PhD Robert Orlowski, MD, PhD Francesco Passamonti, MD Krina K. Patel, MD, MSc Uwe Platzbecker, MD Barbara Pro, MD Ching-Hon Pui, MD John Radford, MD Jerald Radich, MD Noopur Raje, MD Farhad Ravandi, MD Delphine Rea, MD, PhD Katy Rezvani, MD, PhD Josep-Maria Ribera, MD, PhD Gail J. Roboz, MD Valeria Santini, MD Laurie H. Sehn, MD, MPH John Seymour, MBBS, FRACP, PhD Bijal D. Shah, MD Surbhi Sidana, MD Simona Soverini, PhD Alesandro M. Vannucchi, MD William Wierda, MD, PhD Thomas Witzig, MD Pier Luigi Zinzani, MD, PhD SOHO Publication Committee Sundar Jagannath, MD, Chair Brad S. Kahl, MD Hagop Kantarjian, MD Sagar Lonial, MD, FACP Moshe Talpaz, MD SOHO Scientific Committee Moshe Talpaz, MD, Chair Taha al-Juhaishi, MD Pamela Allen, MD, MSc Elias Anaissie, MD Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD Prithviraj Bose, MD Massimo Breccia, MD Renier Brentjens, MD, PhD Hetty Carraway, MD, MBA Jorge E. Cortés, MD Charles Craddock, CBE, FRCP, FRCPath, DPhil, FMedSci Naval Daver, MD Marco Davila, MD, PhD Michael Deininger, MD, PhD
Courtney D. DiNardo, MD, MSCE Barbara Eichhorst, MD Pierre Fenaux, MD, PhD Adele K. Fielding, MD, PhD Guillermo Garcia-Manero, MD Andre Goy, MD, MS Dieter Hoelzer, MD, PhD Elias Jabbour, MD Sundar Jagannath, MD Tapan Kadia, MD Hagop Kantarjian, MD Partow Kebriaei, MD Eva Kimby, MD, PhD Rami S. Komrokji, MD Marina Konopleva, MD, PhD Mary Jo Lechowicz, MD Georg Lenz, MD Jeffrey H. Lipton, MD, PhD, FRCPC Alan List, MD Sanam Loghavi, MD Sagar Lonial, MD, FACP Bob Löwenberg, MD, PhD Peihua Lu, MD Thomas G. Martin, MD John O. Mascarenhas, MD María-Victoria Mateos, MD, PhD Laura C. Michaelis, MD Franck E. Nicolini, MD, PhD Ajay K Nooka, MD, MPH, FACP Eric Padron, MD Jae Park, MD Uday R. Popat, MD Barbara Pro, MD Ching-Hon Pui, MD Prof. Anne Quinquenel, MD, PhD John Radford, MD Jerald Radich, MD Farhad Ravandi, MD Gail J. Roboz, MD Giuseppe Saglio, MD Charles A Schiffer, MD Laurie H. Sehn, MD, MPH Mikkael A. Sekeres, MD, MS Bijal D. Shah, MD Elizabeth Shpall, MD Simona Soverini, PhD Wendy Stock, MD Evangelos Terpos, MD, PhD Fritz Van Rhee, MD, PhD Julie Vose, MD, MBA Eunice S. Wang, MD Andrew Wei, MBBS, PhD Jason R. Westin, MD, MS, FACP William Wierda, MD, PhD Maurizio Zangari, MD Pier Luigi Zinzani, MD, PhD
Volume 25, Number 8 August 2025 Senior Editor-in-Chief Sundar Jagannath, MD New York, New York Editors-in-Chief Brad Kahl, MD St. Louis, Missouri Hagop M. Kantarjian, MD Houston, Texas Sagar Lonial, MD Atlanta, Georgia Lymphoma Associate Editors Martin Heinz Dreyling, MD München, Germany Mehdi Hamadani, MD Milwaukee, Wisconsin Matthew Lunning, MD Omaha, Nebraska Mark Roschewski, MD Bethesda, Maryland Myeloma Associate Editors Ajai Chari, MD San Francisco, California Mariateresa Fulciniti, PhD Boston, Massachusetts Morie Gertz, MD Rochester, Minnesota Amrita Krishnan, MD Duarte, California Roberto Mina, MD Torino, Italy Enrique Ocio, MD, PhD Santander, Spain Evangelos Terpos, MD, PhD Athens, Greece Leukemia Associate Editors Martha Arellano, MD Atlanta, Georgia Ali Bazarbachi, MD Beirut, Lebanon Prithviraj Bose, MD Houston, Texas Meletios A. Dimopoulos, MD Athens, Greece Pierre Fenaux, MD, PhD Bobigny, France Guillermo Garcia-Manero, MD Houston, Texas Armin Ghobadi, MD Saint Louis, Missouri Rami Komrokji, MD Tampa, Florida John Mascarenhas, MD New York, New York Susan O’Brien, MD Orange, California Ching-Hon Pui, MD Memphis, Tennessee Valeria Santini, MD Florence, Italy Moshe Talpaz, MD Ann Arbor, Michigan William G. Wierda, MD, PhD Houston, Texas JoséMaría Ribera, MD, PhD Barcelona, Spain Lymphoma Editorial Board Stefan Barta, MD, MS, MRCP Philadelphia, Pennsylvania Danielle Brander, MD Durham, North Carolina Paolo Caimi, MD Cleveland, Ohio Jonathon Cohen, MD, MS Atlanta, Georgia Alex Herrera, MD Duarte, California Brian Hill, MD, PhD Cleveland, Ohio Manali Kamdar, MD Aurora, Colorado Vaishalee Kenkre, MD Madison, Wisconsin Lale Kostakoglu Shields, MD, MPH Charlottesville, Virginia Daniel Landsburg, MD Philadelphia, Pennsylvania Neha Mehta-Shah, MD Saint Louis, Missouri Gr zegor z Nowakowski, MD Rochester, Minnesota Steven Park, MD Charlotte, North Carolina Tycel Phillips, MD Duarte, California Craig Portell, MD Charlottesville, Virginia Peter Riedell, MD Chicago, Illinois Bijal Shah, MD Tampa, Florida Jakub Svoboda, MD Philadelphia, Pennsylvania David T. Yang, MD Madison, Wisconsin Myeloma Editorial Board Rachid Baz, MD Tampa, Florida Meral M. Beksac, MD Ankara, Turkey Wee Joo Chng, MB ChB, PhD Singapore, Singapore Mattia D’Agostino, MD Torino, Italy Michel Delforge, MD, PhD Leuven, Belgium Hermann Einsele, MD Würzburg, Germany Nisha Joseph, MD Atlanta, Georgia Efstathios Kastritis, MD Athens, Greece Xavier Leleu, MD, PhD Poitiers, France Philippe Moreau, MD Nantes, France Paola Neri, MD, PhD Calgary, Alberta, Canada Charlotte Pawlyn, PhD London, United Kingdom Rao H. Prabhala, PhD Boston, Massachusetts Hang Quach, MD Melbourne, Australia Karthik Ramasamy, MD Oxford, United Kingdom Joshua Richter, MD New York, New York Fredrik Schjesvold, MD Oslo, Norway Cyrille Touzeau, MD, PhD Nantes, France Sonja Zweegman, MD, PhD Amsterdam, Netherlands Ajay Nooka, MD Atlanta, Georgia Leukemia Editorial Board Anjali Advani, MD Cleveland, Ohio Iman Abou Dalle, MD Beirut, Lebanon Naval G. Daver, MD Houston, Texas James Foran, MD, FRCP Jacksonville, Florida Carraway Hetty, MD Cleveland, Ohio Nitin Jain, MD, MSPH Houston, Texas Tapan M. Kadia, MD Houston, Texas Aaron Logan, MD, PhD San Francisco, California Abhishek Maiti, MD Houston, Texas Lucia Masarova, MD Houston, Texas Naveen Pemmaraju, MD Houston, Texas Pia Raanani, MD Petah Tikva, Israel Farhad Ravandi, MD Houston, Texas Philipe Rousselot, MD, PhD Le Chesnay, France Bijal Shah, MD Atlanta, Georgia Jamile Shammo, MD, FACP, FASCP Chicago, Illinois Eunice Wang, MD Buffalo, New York Pier Luigi Zinzani, MD Bologna, Italy Maro Ohanion, DO Houston, Texas Publisher Claudia Willmes Mississippi, USA Index Medicus/PubMed (NLM), Journal Citation Reports/ Science Edition (Thomson ISI), Cambridge Scientific Abstracts (CSA/CIG), CINAHL: Cumulative Index to Nursing & Allied Health Literature (EBSCO), Current Contents®/ Clinical Medicine (Thomson ISI), EMBASE/Excerpta Medica (Elsevier), Science Citation Index Expanded™ (Thomson ISI), Science Citation Index® (Thomson ISI), SCOPUS (Elsevier), Web of Science® (Thomson ISI) Volume 25, Supplement 1 September 2025
Volume 25, Number 8 August 2025 Clinical Lymphoma, Myeloma & Leukemia (ISSN 2152-2650) is published monthly by Elsevier Inc., 1600 John F. Kennedy Boulevard, Suite 1600, Philadelphia, PA 1910, United States. POSTMASTER: Send address changes to Clinical Lymphoma, Myeloma & Leukemia , Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA. Submit online: https://www.evise.com/profile/#/CLML/login . Annual subscription rates United States and possessions: individual, $231. All other coun- tries: individual, $256. Orders, claims, and journal inquiries Please visit our Support Hub page https://service.elsevier.com for assistance . Advertising information: Advertising orders and enquiries can be sent to: USA, Canada and South America: Jaichand Ramsaroop, Advertising Sales Depart- ment, Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169, USA; phone: (+1) (212) 633-3690; fax: (+1) (212) 633- 3820; e-mail: j.ramsaroop@elsevier.com. Reprints To order 100 or more reprints for educational, commercial, or promotional use, contact the Commercial Reprints Department, Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169; E-mail: reprints@elsevier.com. Author inquiries For inquiries relating to the submission of articles (including elec- tronic submission where available) please visit this journal’s home- page. You can track accepted articles at http://www.elsevier.com/ trackarticle and set up e-mail alerts to inform you of when an ar- ticle’s status has changed. Also accessible from here is information on copyright, frequently asked questions and more. Contact de- tails for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher. Funding body agreements and policies Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as spec- ified as conditions of their grant awards. To learn more about exist- ing agreements and policies please visit http://www.elsevier.com/ fundingbodies . Copyright ©2025 Elsevier Inc. All rights reserved. This journal and the individual contributions contained in it are protected under copy- right, and the following terms and conditions apply to their use in addition to the terms of any Creative Commons or other user license that has been applied by the publisher to an individual article: Photocopying Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission is not required for photocopying of articles published under the CC BY license nor for photocopying for non-commercial purposes in accordance with any other user license applied by the publisher. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or system- atic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. For information on how to seek permission visit www.elsevier.com/permissions or call: ( + 44) 1865 843830 (UK) / ( + 1) 215 239 3804 (USA). Derivative Works Users may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions or companies. Other than for articles published under the CC BY license, permission of the publisher is required for resale or distribution outside the subscribing institution or company. For any subscribed articles or articles published under a CC BY-NC-ND license, permis- sion of the publisher is required for all other derivative works, including compilations and translations. (please consult www.elsevier.com/permissions). Storage or Usage Except as outlined above or as set out in the relevant user license, no part of this pub- lication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Permissions For information on how to seek permission visit www.elsevier.com/permissions or call: ( + 1) 800-523-4069 x 3808 (please consult www.elsevier.com/permissions). Author rights Author(s) may have additional rights in their articles as set out in their agreement with the publisher (more information at http://www.elsevier.com/authorsrights ). Notice Journals published by Elsevier comply with applicable product safety requirements. For any product safety concerns or queries, please contact our authorized representative, Elsevier B.V., at productsafety@elsevier.com Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments contained herein. Health care practitioners must exercise their professional judgement and make all treatment-related decisions based solely on the specific conditions of each patient. Because of rapid advances in the medical sciences, independent verification of diagnoses and drug dosages should always be made. The content is provided “as-is” and Elsevier makes no representations or warranties, whether express or implied, as to the accuracy, completeness, or adequacy of any content. To the fullest extent permitted by law, Else- vier assumes no responsibility for any damages, adverse events, or liability arising from use of information contained herein including for any injury and/or damage to persons or property, whether as a matter of product liability, negligence or otherwise. Inclusion of any advertising material in this publication does not constitute a guarantee or endorsement of the quality or value of such product or service or of any of the representations or claims made by the advertiser. Printed by Sheridan at 69 Lyme Road, Hanover, NH 03755 ∞ �The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper) Volume 25, Supplement 1 September 2025
www.soho.click/2025 Society of Hematologic Oncology Thirteenth Annual Meeting September 3–6, 2025 Location: Houston, Texas, USA & Virtual Venue (Hybrid Event) Table of Contents Message from the Chairpersons ................................................................................................S1 Extended Abstracts EXABS-102-AML: How to Select Intensive vs Lower-Intensity Therapy in Younger Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3 Amir Fathi, MD EXABS-103-ALL: MRD and Its Management in Ph+ ALL ......................................................................S5 Heike Pfeifer, MD EXABS-104-ALL: Measurable Residual Disease and Its Management in Acute Lymphoblastic Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . S7 Ibrahim Aldoss, MD EXABS-106-LYM: Early-Stage Hodgkin Lymphoma: Are We Ready for Novel Agents? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S9 Joseph G. Schroers-Martin, MD and Ranjana Advani, MD EXABS-107-LYM: Management of Hodgkin Lymphoma in Older Patients .....................................................S12 Ryan Lynch, MD EXABS-108-LYM: Integrating Circulating Tumor DNA into the Management of Hodgkin Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . .S14 Sven Borchmann, MD, PhD EXABS-110-NHL: The Optimal Management of Waldenström Macroglobulinemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S16 Jorge J. Castillo, MD EXABS-111-LYM: What Is Grey Zone Lymphoma and How Do We Treat It? ..................................................S19 Kieron Dunleavy, MD EXABS-112-CML: QoL: What Do Patients Really Want? ......................................................................S21 Kathryn E. Flynn, PhD EXABS-113-CML: Chronic Myeloid Leukemia in Low- and Middle-Income Countries, Including Discontinuation . . . . . . . . . . . . .S23 Pat Garcia-Gonzalez, MSc EXABS-114-CML: TKI De-Escalation: The “Downgrading” Impact on CMLTreatment........................................S25 Elisabetta Abruzzese, MD, PhD, Malgorzata Monika Trawinska, MD, PhD, Monica Crugnola, MD, and Simona Bernardi, PhD
EXABS-115-MPN: Predictive Markers for Ruxolitinib in Myelofibrosis ........................................................S28 Francesca Palandri, MD, PhD, Alessandra Dedola, MD, and Filippo Branzanti, MSc EXABS-117-MPN: New Therapies and Targeted Treatments: MDS/MPN Overlap Syndromes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S31 Michael R. Savona, MD EXABS-118-MDS: Progress in CHIP/CCUS ..................................................................................S34 Jayanshu Jain, MD and Uma Borate, MBBS EXABS-122-MM: Therapy for SMM: Emerging Data..........................................................................S36 Saad Z. Usmani, MD, MBA, FACP, FASCO EXABS-128-CT: Best of Cell Therapy for Lymphoma: What We Learned in 2024 and 2025 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S37 Hanan Alharthy, MD and Sairah Ahmed, MD EXABS-129-CT: What We Learned in 2024 and 2025: Best of Stem Cell Transplant ...........................................S42 Alexandra Gomez-Arteaga, MD EXABS-134-ALL: Management of High-Risk Philadelphia Chromosome-Positive ALL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S44 Walid Macaron, MD, MSc and Nicholas J. Short, MD EXABS-136-LYM: Management of Burkitt Lymphoma ........................................................................S47 Ariela Noy, MD EXABS-137-LYM: Management of Primary CNS Lymphoma: Young and Old..................................................S48 Paolo Fiore, MD, Teresa Calimeri, MD, PhD, and Andrés J. M. Ferreri, MD EXABS-143-CML: Non-ABL1 Mutations in Newly Diagnosed Patients: Implications ...........................................S52 Susan Branford, PhD, FFSc (RCPA) EXABS-144-CML: Predicting Outcomes in Chronic Myeloid Leukemia .......................................................S54 Nicholas C.P. Cross, PhD EXABS-146-MPN: Individualizing Treatment Selection in MF.................................................................S55 Prithviraj Bose, MD EXABS-153-MM: Monoclonal Gammopathy of Clinical Significance ..........................................................S57 Despina Fotiou, MD and Meletios Athanasios Dimopoulos, MD, PhD EXABS-154-CLL: Richter’s Syndrome: Preclinical Insight .....................................................................S59 Elisa Ten Hacken, PhD EXABS-156-CLL: New Immunotherapeutic Horizons in Richter’s Transformation: Synergistic Approaches with Targeted Agents ..............................................................................................................S60 Arnon P. Kater, MD, PhD EXABS-157-CT: Advancements in Immune Effector Cell-Associated HLH-Like Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S63 Annamaria Ballweg, MD, Xavier Deschênes-Simard, MD, and William T. Johnson, DO EXABS-160-ALL: Novel Therapies in T-ALL: From CAR-T to Novel Targets ...................................................S67 Ryan J. Summers, MD and David T. Teachey, MD EXABS-166-ALL: TP53 Abnormalities in ALL: Impact on Outcomes and Optimal Management With Modern Therapies . . . . . . .S71 Roberta S. Azevedo, MD and Nicholas J. Short, MD EXABS-171-MDS: Progress in Higher-Risk Myelodysplastic Syndromes .......................................................S74 Amy E. DeZern, MD, MHS EXABS-172-MDS: Improving Transplant Outcomes in Myelodysplastic Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S77 Uday R. Popat, MD, MBA EXABS-176-AML: How to Best Incorporate FLT3 Inhibitors in the Management of FLT3-Mutated AML .......................S79 Alexander E. Perl, MD EXABS-177-AML: IDH Inhibitor Combination Strategies in IDH-Mutated AML ..............................................S81 Jennifer Marvin-Peek, MD and Courtney DiNardo, MD, MSCE
EXABS-181-AML: Novel Strategies in High-Risk AML: Focus on Immune-Based Strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S84 David A. Sallman, MD EXABS-184-MPN: Refining Diagnosis, Prognosis, and Management of MPNs With AI/ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S85 Rosalin Cooper, MBChB, PhD, FRCPath, Emily Thomas, PhD, Xuezi Hu, BA, Dawood Muhammad, PhD, Hosuk Ryou, PhD, Korsuk Sirinukunwattana, PhD, Alan Aberdeen, BA, Sharon Ruane, PhD, Tim Ebsworth, MB BChir, Anna Sozanska, MBBChir, Carlo Pescia, MD, Jens Rittscher, PhD, and Daniel Royston, MBChB, BMSC, Dphil, FRCPath EXABS-185-MPN: Novel Therapies in Essential Thrombocythemia and Polycythemia Vera . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S87 Chi-Joan How, MD and Gabriela Hobbs, MD EXABS-187-MPN: When and How to Optimize JAK Inhibitor Therapy in Myelofibrosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S90 Francesca Palandri, MD, PhD, Chiara Sartor, MD, PhD, and Filippo Branzanti, MSc EXABS-188-MPN: Is Combination Therapy Here for MPN?...................................................................S93 John Mascarenhas, MD EXABS-189-MPN: Transplantation in Myelofibrosis: Who and When?.........................................................S95 Nihar Desai, MD, DM and Vikas Gupta MD, FRCP, FRCPath EXABS-191-CML: Evolving Algorithms Based on New Drug Approvals: What Have We Gained? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .S98 Jorge Cortes, MD EXABS-192-CML: Co-Targeting in CML .................................................................................. S100 Mhairi Copland, BSs, MBChB, PhD EXABS-194-CML: Is Targeting BCR::ABL1 Alone Sufficient? NO ........................................................... S103 Timothy P. Hughes, MD, MBBS EXABS-199-MM: Future on Bispecifics and Antibody-Drug Conjugates ..................................................... S106 Sabarish Ayyappan, MD, James Sanchez, PhD, and Amrita Krishnan, MD EXABS-202-MM: Mechanisms of Resistance to T-Cell-Based Immunotherapies in Multiple Myeloma . . . . . . . . . . . . . . . . . . . . . . . . . S108 Paola Neri, MD, PhD EXABS-205-CLL: Data From NGS: What to Do With Additional Abnormalities Found at Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . S109 Fabrizio Mavilia, MD, Francesca Martini, MD, and Lydia Scarfò, MD EXABS-207-CLL: Debate: Progression on Covalent BTK Inhibitors—Change to Non-Covalent BTK Inhibitors . . . . . . . . . . . . . . . S111 Jeff P. Sharman, MD EXABS-208-CLL: Debate: Progression on Covalent BTK Inhibitors—Change to Venetoclax-Based Therapy . . . . . . . . . . . . . . . . . . . S113 Nawar Maher, MD and Gianluca Gaidano, MD, PhD EXABS-210-CLL: New Targets and Drugs on the Horizon in Chronic Lymphocytic Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S116 Meghan C. Thompson, MD EXABS-213-TCL: Genetics of PTCL: From Bench to Bedside................................................................ S120 Jaehyuk Choi, MD, PhD EXABS-215-TCL: Moving Beyond Romidepsin: New Strategies for Relapsed/Refractory PTCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S121 Jasmine Zain, MD EXABS-216-TCL: Can Immunotherapy Become a Reality for T-Cell Lymphoma? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S123 Anne W. Beaven, MD EXABS-219-IBCL: Follicular Lymphoma: Does the Choice of Frontline Treatment Matter? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S126 Neha Akkad, MD and Christopher Flowers, MD, MS EXABS-221-IBCL: Novel Immunotherapy Combinations in Indolent Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S129 Mika Geva, MD and Lorenzo Falchi, MD EXABS-222-IBCL: Relapsed/Refractory Indolent Lymphoma: Options Beyond Immunotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S133 Alessandro Broccoli, MD, PhD and Pier Luigi Zinzani, MD, PhD
EXABS-227-ABCL: Holding and Bridging Therapy Selection in Relapsed/Refractory Aggressive B-Cell Lymphoma ............................................................................................... S135 Gloria Iacoboni, MD EXABS-229-ABCL: Treatment of Rare Subtypes of Aggressive B-Cell Lymphoma: T-Cell/Histiocyte-Rich LBCL, EBV-Positive DLBCL, and Plasmablastic Lymphoma........................................................................ S139 Mark Roschewski, MD EXABS-230-ABCL: Potential of AI Remote Patient Monitoring for Lymphoma ............................................................................................................. S142 Jonas Paludo, MD EXABS-232-MCL: AI Models for Diagnosis and Prognostication in MCL .................................................... S145 Eric D. Hsi, MD EXABS-234-MCL: Management of Mantle Cell Lymphoma in Patients Previously Treated with Covalent BTK Inhibitors ...................................................................................... S146 Krish Patel, MD EXABS-235-MCL: High-Risk MCL: Definition and Innovative Treatment Strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S148 Reem Karmali, MD, MS EXABS-242-CT: AI Agents Transforming Care in Transplantation and Cellular Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S152 Amin T. Turki, MD, PhD EXABS-247-NQ: Next Questions: Acute Lymphoblastic Leukemia ........................................................... S154 Hannah Goulart, MD, Hagop Kantarjian, MD, and Elias Jabbour, MD EXABS-248-NQ: Acute Myeloid Leukemia: Next Questions ................................................................. S157 Farhad Ravandi, MD EXABS-255-NQ: Next Questions: Mantle Cell Lymphoma .................................................................. S159 Tycel Phillips, MD and Jon Weiss, MD Oral Abstracts Oral Abstract Presentations ................................................................................................ S162 Poster Presentations Poster Presentations ....................................................................................................... S166 Submitted Abstracts Acute Lymphoblastic Leukemia............................................................................................. S332 Acute Myeloid Leukemia ................................................................................................... S391 Chronic Lymphocytic Leukemia ............................................................................................ S511 Chronic Myeloid Leukemia................................................................................................. S550 Myelodysplastic Syndromes................................................................................................. S598 Myeloproliferative Neoplasms .............................................................................................. S645 Hodgkin Lymphoma ....................................................................................................... S696 Aggressive B-Cell Lymphoma ............................................................................................... S720 Indolent B-Cell Lymphoma ................................................................................................ S805 Mantle Cell Lymphoma .................................................................................................... S845 T-Cell Lymphoma ......................................................................................................... S858 Multiple Myeloma ......................................................................................................... S887 Cellular Therapy ........................................................................................................... S997
Indices Author Index ............................................................................................................. S1070 Keyword Index............................................................................................................ S1121 Disclaimer Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Although all advertising material is expected to conform to ethical and medical standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer. Publication of this Abstract supplement is supported by the Society of Hematologic Oncology.
Message from the Chairpersons On behalf of the organizing committees, it is our pleasure to welcome you to the thirteenth annual meeting of the Society of Hematologic Oncology (SOHO). As many of you know, SOHO was established in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies. Since that time, SOHO has grown from a membership base of 400 to over 10,000 in 2025. Organized by its founders and world class committees, SOHO is the only society specific to this field. During the 3.5-day annual meeting, we will participate in a number of educational sessions including in-person didactic lectures, meet-theprofessor sessions, debates, plenary sessions, poster presentations, oral abstract presentations and other interactive exchanges and informal engagement experiences. As a hybrid event, all SOHO 2025 general sessions will be available for live and post-session viewing on the virtual platform. The theme of SOHO 2025 is “Translating Knowledge Worldwide”as it relates to the field of hematologic oncology. Topics will include Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, T-Cell Lymphoma, Mantle Cell Lymphoma, Aggressive B-Cell Lymphoma, Indolent B-Cell Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Multiple Myeloma and Cellular Therapy. We hope you will find the meeting productive, informative, and enjoyable. We would like to thank all SOHO members, attendees and industry partners whose contributions and participation have been essential to the success of the society. With warmest regards, Phillip Scheinberg, MD Hagop Kantarjian, MD President & Chair, SOHO Secretary, SOHO Professor and Chair Department of Leukemia The University of Texas MD Anderson Cancer Center S1
EXABS-102-AML How to Select Intensive vs Lower-Intensity Therapy in Younger Patients Amir Fathi, MD1* 1Massachusetts General Hospital, Boston, Massachusetts, USA *Corresponding author: afathi@mgh.harvard.edu Keywords AML, venetoclax, intensive chemotherapy, hypomethylating agents Intensive vs Lower-Intensity Treatment for AML: An Evolving Paradigm Acute myeloid leukemia (AML) was incurable 60 years ago. While there have been improvements in therapeutic outcomes over time, successful treatment remains a challenge. For more than four decades, the standard treatment for functionally fit, newly diagnosed AML patients has consisted of intensive chemotherapy (IC) with various doses and schedules of anthracyclines and cytarabine, studied in regimens devised by early Cancer and Leukemia Group B (CALGB) trials.1,2 The 7+3 regimen—7 days of infusional cytarabine given concurrently with 3 days of an anthracycline—emerged from the CALGB-7421 trial3and has been extensively and pervasively used for decades as first-line IC in AML. With this regimen, outcomes are frequently suboptimal, especially in older patients and those with high-risk AML.4 Some incremental progress was accomplished over the last decade for IC, as CPX-351, a liposomal anthracycline- and cytarabine-containing product, demonstrated improved survival when compared to conventional 7+3 in secondary AML5 andwas subsequently approved in 2017. However, one can argue that more than any other agent, the clinical development of the BCL2 inhibitor venetoclax has transformed the therapeutic landscape of AML in general—particularly for older, induction-ineligible patients. When combined with hypomethylating agent (HMA) therapies (decitabine and azacitidine) in single-arm clinical trials, rates of response among older patients were remarkable, with a composite remission rate (CCR) of 67% and a reported median overall survival (OS) of 17.5 months. These results were even more impressive in certain molecular subgroups (eg, IDH1/2- or NPM1-mutated patients).6 These outcomes certainly compared favorably to those seen with the experience of IC among older ICeligible patients. In fact, the CCR associated with HMA-venetoclax among older, less robust patients approximated that historically seen with IC (65%–70%) among younger, functionally fit patients. The phase 3 randomized, placebo-controlled Viale A study of azacitidine and venetoclax (aza-ven) revealed a statistically significant OS advantage, with a median OS of 14.7 months (vs 9.6 months). The tolerability of HMA-venetoclax, a predominantly outpatient regimen, was also highly promising,7 leading to a regulatory approval for older patients in the US in 2020. It is well known that traditional IC is very toxic, requiring weeks of hospitalization and associated with severe marrow suppression that increases the risk of bleeding, infections, and death, as well as other complications, including nutritional deficiency, gastrointestinal (GI) side effects, mucositis, rash, and risk of cardiac complications and secondary malignancy.8 There is also the increased likelihood of prolonged critical illness, transition to intensive care, psychosocial traumas associated with prolonged stay and complications, and markedly increased cost from the burden of care. Despite some improvement over time, treatment-related mortality from IC remains nontrivial.9 Starting a decade ago, intriguing data began to emerge, suggesting that among younger patients with higher-risk disease, HMA therapies may be preferable. One study assessed the activity of 10-day decitabine among 54 newly diagnosed AML patients aged≥60years. Among these, all TP53-mutated participants responded, with many achieving marrow remissions.10 Although subsequent studies did not mirror these highly impressive findings, they suggested that HMA therapy may be just as effective and more tolerable when compared to IC in this population. Lubbert and colleagues compared 10-day decitabine with 7+3 among IC-eligible patients. Although the CCR was lower among the former group, there were no statistically significant differences in bridging to allogeneic transplant and OS.11 More recently, several groups have compared, in retrospective fashion, populations receiving HMA-venetoclax and IC, mostly revealing similar response and survival data between the two, with decreased hospitalizations and toxicity and improved tolerability for HMA-venetoclax.12–14 A recently published Chinese study prospectively compared HMA-venetoclax to IC and reported improvements on remission rates with the former.15 Based on the above considerations and the current predominantly retrospective data suggesting efficacy and enhanced tolerability with HMA-venetoclax in traditionally IC-eligible patients, we designed and recently completed accrual to a multicenter, randomized (1:1), phase 2 study that tested the hypothesis that treatment with aza-ven leads to improved event-free survival (EFS) among fit patients with newly diagnosed AML when compared to IC (7+3 or CPX-351). We hypothesized that the CCR for aza-ven will be at least similar to IC, S3
with an improved safety profile, fewer and less prolonged hospitalizations, lower cost of care, and improved candidacy for transplantation. We enrolled newly diagnosed, IC-eligible AML patients, aged ≥18 years. FLT3-mutated and core-binding factor (CBF)-AML were excluded, as were younger NPM1-mutated patients. The primary outcome was EFS, where an event was defined as progressive disease, change in therapy due to leukemic persistence, disease relapse, hospice, or death. Patients were stratified by age (≥65 vs <65 years). There was also a preselection prior to randomization for either 7+3 or CPX-351 for those subsequently assigned to the IC arm. The study was designed to enroll 172 patients, 86 allocated per arm, to achieve 85% power to detect a treatment difference at the one-sided 10% type I error rate. A futility analysis was triggered after accruing 50% of the subjects and observing 40% EFS, which was overcome. Secondary endpoints included response rates, OS, toxicity, rate of measurable residual disease (MRD), number and duration of hospitalizations, cost, and quality-of-life measures. We hope to present interim results in the very near future. These retrospective and prospective data may very well gradually change the landscape of AML for younger and fit patients with AML, but there will be remaining questions that emerge. For example, are there certain groups that would do better with HMA-venetoclax and vice versa? As of now, the only IC-eligible group of patients in whom HMA-based therapy is being pervasively used are those with biallelic TP53 mutations, since this group does so poorly with the array of treatments available for AML, and more gentle therapy seems to be as effective as the more toxic IC. Over time, additional groups of ICeligible AML patients may also be more appropriate to consider for HMA-venetoclax, depending on data that emerge from ongoing and future trials. These data would include response rates, MRD clearance, bridging to transplant, and survival outcomes. It is very possible that in the not-too-distant future, HMA-venetoclax will serve as the therapeutic backbone for the majority of treatment options offered to AML patients, regardless of age or functional status. References 1. Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32(4): 507–23. 2. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 1981; 58(6): 1203–12. 3. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood1982; 60 (2): 454–62. 4. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. NEngl JMed 1999; 341(14): 1051–62. 5. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol 2018; 36(26): 2684–92. 6. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 2019; 133(1): 7–17. 7. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. NEngl JMed 2020; 383(7): 617–29. 8. Buckley SA, Othus M, Vainstein V, Abkowitz JL, Estey EH, Walter RB. Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. American Journal of Hematology 2014; 89(4): 423–8. 9. Othus M, Kantarjian H, Petersdorf S, et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson. Leukemia2014; 28 (2): 289–92. 10. Welch JS, Petti AA, Ley TJ. Decitabine in TP53Mutated AML. NEngl JMed 2017; 376(8): 797–8. 11. Lubbert M, Wijermans PW, Kicinski M, et al. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. Lancet Haematol 2023; 10(11): e879–e89. 12. Cherry EM, Abbott D, Amaya M, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv 2021; 5(24): 5565–73. 13. Matthews AH, Perl AE, Luger SM, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv 2022; 6(13): 3997– 4005. 14. Shimony S, Bewersdorf JP, Shallis RM, et al. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 2024; 38(4): 762–8. 15. Lu J, Xue S, Wang Y, et al. Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML. Blood 2025. S4
EXABS-103-ALL MRD and Its Management in Ph+ ALL Heike Pfeifer, MD1* 1Department of Hematology and Oncology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt *Corresponding author: h.pfeifer@em.uni-frankfurt.de Keywords ALL, Philadelphia chromosome, acute lymphoblastic leukemia, BCR::ABL1, measurable residual disease Introduction For decades, Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been a very high-risk disease with overall survival rates below 20% without allogenic stem cell transplantation (SCT). With the integration of tyrosine kinase inhibitors into primary therapy, a substantial increase in overall survival began.1,2 Several study groups have demonstrated that the integration of immunotherapies like blinatumomab can further improve outcomes.3,4 These drugs have been successfully enrolled as salvage regimens in relapsed and refractory Ph+ ALL. Their integration into induction and consolidation therapy may further benefit patients. However, whether allogeneic SCT is still needed remains the subject of many clinical studies. One innovative trial in this respect is the EVOLVE trial, conducted within the GMALL study group. The primary objective is to demonstrate non-inferiority in the overall survival of patients with Ph+ ALL who achieve molecular complete remission following treatment with a tyrosine kinase inhibitor (TKI) and chemotherapy alternating with blinatumomab compared to those who proceed to SCT at the end of the therapy.5 The treatment regimen is guided by minimum residual disease (MRD) assessment. Management of MRD Techniques Three different methods for the detection of MRD are available. MRD can be assessed by 1) quantitative real-time PCR for detecting fusion transcripts like BCR::ABL1, 2) quantitative real-time PCR or next-generation sequencing (NGS)-based assays for immunoglobulin (IG)/T-cell receptor (TCR) gene rearrangements, or 3) flow cytometry.6 The EuroMRD consortium has standardized MRD measurement for all three of these techniques. EuroMRD is a consortium of more than 60 laboratories over the entire world, mainly within Europe. Quality control assessments are performed twice a year. For example, using harmonized protocols and result interpretation criteria, interlaboratory variation in BCR::ABL1 fusion-based MRD detection typically falls within one logarithmic unit.7,8 Quantitative PCR methods are more sensitive than flow cytometrybased methods and are often routinely used. The main advantage of the PCR methods is the highly standardized methodology. One of the major disadvantages is that for IG/TCR rearrangements, a reference sample with a high blast count from the initial diagnosis is needed to define the leukemia-associated rearrangements and to design the patient-specific PCR assay.8 Amplicon-based NGS, with high coverage of patient-specific clones or additional leukemiaspecific genetic markers (eg, IKZFdeletions), is also used in countries not participating in EuroMRD, like the USA.9 MRD should be monitored regularly during induction, consolidation, and maintenance treatments. In B-cell ALL (B-ALL), bone marrow should be preferred for MRD analysis due to a higher sensitivity compared to peripheral blood.10 Comparison of Results within Study Groups The prognostic relevance of MRD may depend on the treatment approach. In the GMALL 08 trial for younger patients with Ph+ ALL who received a combination of imatinib and high-dose chemotherapy followed by allogeneic SCT, MRD measured by quantitative realtime PCR for BCR::ABL1 did not show a prognostic impact on overall survival.11 The GIMEMA group in the D-ALBA trial found that patients treated with a combination of dasatinib and steroids who achieved complete molecular remission by day 85 had improved disease-free survival. A difference between the studies was the rate of allogeneic SCT—98% of patients in the GMALL 08 trial underwent SCT.12 The GRAAPH2014 trial for younger patients, consisted of 4 cycles of reduced-intensity chemotherapy with nilotinib followed by hematopoietic SCT. Quantitative real-time PCR was used to measure BCR::ABL1 transcripts and IG/TR rearrangements in parallel. Notably, 43% of patients exhibited residual BCR::ABL1-positive non-ALL cells, indicating a multilineage Ph+ ALL Only MRD positivity based on IG/TR rearrangements was associated with lower disease-free survival. MRD response based onBCR::ABL1transcript levels failed to predict outcomes. Patients with multilineage Ph+ ALL had similar disease-free survival.13 With the genetic analysis of transcriptomes, patients with multilineage Ph+ ALL can be identified at diagnosis. The therapeutic impact of these findings—especially in those with lymphoid only vs multilineage Ph+ ALL—is not clarified to date. Genetic classification may help guide therapy. In a cohort of 327 patients from the GMALL study who were analyzed using transcriptome sequencing, a subgroup of patients with lymphoid Ph+ S5
ALL carrying an IKZF+ signature exhibited inferior disease-free survival.14 These findings were also observed in the GIMEMA study.2 Summary In upcoming trials, MRD information combined with genomic profiling at initial diagnosis can be used for risk stratification. Further studies are needed to address the questions: Do we need a combination of different MRD techniques? What is the prognostic role of early MRD negativity? Lastly, how can a molecular relapse be seen at a very early stage? References 1. Kantarjian H, Short NJ, Jain N, et al. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80months follow-up results. Am J Hematol 2023;98:493–501. 2. Foà R, Bassan R, Vitale A, et al. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. The New England Journal of Medicine 2020;383:1613–23. 3. Jabbour E, Short NJ, Jain N, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 2023;10:e24–e34. 4. Chiaretti S, Leoncin M, et al. Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820. Blood 2024;144(Supplement 1):835. 5. Lang F, Pfeifer H, et al. A Multicentre, Randomized Trial in Adults with de novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia to Assess the Efficacy of Ponatinib versus Imatinib in Combination with LowIntensity Chemotherapy, to Compare End of Therapy with Indication for Stem Cell Transplantation versus Tyrosine Kinase Inhibitor, Blinatumomab, and Chemotherapy in Optimal Responders, and to Evaluate Blinatumomab in Suboptimal Responders (GMALL-EVOLVE). Oncol Res Treat. 2024;47(9):430–433. 6. Short NJ, Jabbour E, Albitar M, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. Am J Hematol 2019;94:257–65. 7. Pfeifer H, Cazzaniga G, et al. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia. 2019 Aug;33 (8):1910–1922. 8. van der Velden VHJ, Dombrink I, et al. Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines. Leukemia. 2024 Jun;38(6):1315–1322. 9. Ladetto M, Bruggemann M, Monitillo L, et al. Nextgeneration sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 2014; 28(6): 1299–307. 10. Wood B, Wu D, Crossley B, et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood 2018; 131(12): 1350–9. 11. Pfeifer H, Lang F, etal. Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation. Blood 2024;144(Supplement 1):840. 12. Robin Foà R, Bassan R, et al. Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult PhiladelphiaPositive ALL. J Clin Oncol. 2024 Mar 10;42(8):881–885. 13. Kim R, Chalandon Y, et al. Significance of Measurable Residual Disease in Adult Philadelphia ChromosomePositive ALL: A GRAAPH-2014 Study. J Clin Oncol. 2024 Sep 10;42(26):3140–3150. 14. Bastian L, Beder T, et al. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL. Blood. 2024 Apr 4;143 (14):1391–1398. S6
RkJQdWJsaXNoZXIy MjYwNTA2NQ==